A detailed history of China Universal Asset Management Co., Ltd. transactions in Insmed Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 33,052 shares of INSM stock, worth $2.44 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
33,052
Previous 18,942 74.49%
Holding current value
$2.44 Million
Previous $1.27 Million 90.07%
% of portfolio
0.27%
Previous 0.18%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$62.0 - $79.01 $874,820 - $1.11 Million
14,110 Added 74.49%
33,052 $2.41 Million
Q2 2024

Jul 19, 2024

SELL
$22.0 - $69.71 $211,794 - $671,098
-9,627 Reduced 33.7%
18,942 $1.27 Million
Q1 2024

Apr 29, 2024

BUY
$25.72 - $29.94 $309,102 - $359,818
12,018 Added 72.61%
28,569 $775,000
Q4 2023

May 21, 2024

SELL
$23.42 - $31.74 $281,461 - $381,451
-12,018 Reduced 42.07%
16,551 $512,000
Q4 2023

Jan 23, 2024

BUY
$23.42 - $31.74 $301,017 - $407,954
12,853 Added 347.57%
16,551 $513,000
Q3 2023

May 21, 2024

BUY
$19.86 - $26.93 $37,932 - $51,436
1,910 Added 106.82%
3,698 $93,000
Q3 2023

Oct 30, 2023

BUY
$19.86 - $26.93 $37,932 - $51,436
1,910 Added 106.82%
3,698 $93,000
Q2 2023

May 21, 2024

SELL
$16.44 - $21.1 $986 - $1,266
-60 Reduced 3.25%
1,788 $37,000
Q2 2023

Jul 27, 2023

SELL
$16.44 - $21.1 $986 - $1,266
-60 Reduced 3.25%
1,788 $38,000
Q1 2023

May 21, 2024

BUY
$16.26 - $21.73 $7,674 - $10,256
472 Added 34.3%
1,848 $31,000
Q1 2023

Apr 27, 2023

BUY
$16.26 - $21.73 $7,674 - $10,256
472 Added 34.3%
1,848 $32,000
Q4 2022

May 21, 2024

SELL
$16.98 - $23.15 $461,737 - $629,517
-27,193 Reduced 95.18%
1,376 $27,000
Q4 2022

Jan 31, 2023

BUY
$16.98 - $23.15 $4,278 - $5,833
252 Added 22.42%
1,376 $27,000
Q3 2022

Oct 21, 2022

BUY
$20.88 - $28.21 $23,469 - $31,708
1,124 New
1,124 $24,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.